Royal Biologics commenced U.S. launch of the Advanced – Cell™ fusion bone grafting system for orthopedics. Advanced – Cell combines multiple autologous and bone grafting technologies in one convenience kit.
Advanced – Cell comprises:
Maxx™-Cell bone marrow aspiration therapy for various uses in orthopedics, sports medicine and pain management
Bio-Reign™ Bioactive Matrix synthetic osteoconductive porous implant that supports an ideal environment for bone growth
Royal Autograft Harvesting System
Salvatore Leo, CEO and founder of Royal Biologics, said, “By bundling these three technologies into one convenience kit, we can help streamline supply chain disruptions, reduce time in the operating rooms and provide increased value in a low-cost option product matrix. With increased lead times in supply chains and shortages in global resources, we see a tremendous value in offering a product with multiple grafting options, all in one kit and point of care.”
Royal Biologics commenced U.S. launch of the Advanced - Cell™ fusion bone grafting system for orthopedics. Advanced - Cell combines multiple autologous and bone grafting technologies in one convenience kit.
Advanced - Cell comprises:
Maxx™-Cell bone marrow aspiration therapy for various uses in orthopedics, sports medicine and pain...
Royal Biologics commenced U.S. launch of the Advanced – Cell™ fusion bone grafting system for orthopedics. Advanced – Cell combines multiple autologous and bone grafting technologies in one convenience kit.
Advanced – Cell comprises:
Maxx™-Cell bone marrow aspiration therapy for various uses in orthopedics, sports medicine and pain management
Bio-Reign™ Bioactive Matrix synthetic osteoconductive porous implant that supports an ideal environment for bone growth
Royal Autograft Harvesting System
Salvatore Leo, CEO and founder of Royal Biologics, said, “By bundling these three technologies into one convenience kit, we can help streamline supply chain disruptions, reduce time in the operating rooms and provide increased value in a low-cost option product matrix. With increased lead times in supply chains and shortages in global resources, we see a tremendous value in offering a product with multiple grafting options, all in one kit and point of care.”
Copy to clipboard 
